Search results
1 mar 2006 · The standard assessments of neurocognition in schizophrenia are performance-based tests, and clinical trials assessing the impact of new medicines or behavioral therapies on neurocognitive deficits in schizophrenia normally use performance tests as a primary outcome measure.
rently, few psychiatric practitioners measure cognition in their patients. This is perplexing because cognitive measurement is important for confirming the diagnosis of schizophrenia in first-episode psychosis, or distinguishing it from other psychotic disor-ders (such as drug-induced psychosis, brief reactive psyc. Table 1.
Based on the reviewed evidence, we recommend a comprehensive and systematic assessment of neurocognitive and social cognitive domains in schizophrenia, in all phases of the disorder, as well as in subjects at risk to develop psychosis.
We used the “assessment of multiple systematic reviews” (AMSTAR-2) appraisal checklist for the evaluation of methodological quality of meta-analysis. ... Wykes T., Steel C., Everitt B., Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34(3):523–537. doi ...
1 cze 2014 · The book brings together an impressive group of leading researchers who present literature reviews highlighting recent developments in four primary areas: characteristics of cognitive impairment in schizophrenia (section 1), its functional implications and course (section 2), genetic and biological contributions (section 3), and assessment and t...
1 cze 2004 · The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia.
1 kwi 2006 · Cognitive-behavioral therapy (CBT) has a proven role as an adjunct to antipsychotic medication and remediative approaches such as social skills training in the management of residual symptoms of chronic schizophrenia.
